SGEN - Seattle Genetics

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Seagen GAAP EPS of -$1.15 misses by $0.37, revenue of $571M misses by $64.1M
• Pfizer CEO expects Seagen deal to close before year end, or early in 2024
• Seattle Genetics Q3 2023 Earnings Preview
• Pharma, PBMs spar over rising drug costs amid public scrutiny
• Seagen, Genmab update Phase 3 data for uterine cancer therapy
• Seagen/ Astellas succeed in Phase 3 trial for bladder cancer therapy
• Seagen ticks higher as EU approves $43B sale to Pfizer
• Pfizer likely turned over all documents to FTC for Seagen acquistion - report
• Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event
• Regulators looking at impact on innovation in review of Seagen/Pfizer - report
• Pfizer expected to certify compliance with FTC on Seagen deal in 2-3 weeks - report
• Merck succeeds in Phase 3 trial for bladder cancer therapy
• Catalyst watch: Microsoft, Amazon, Oracle, and Intel to Hold High-Profile Events
• 7 stocks to watch on Friday: Detroit Three automakers, Unity Software and more
• Pfizer's $43B deal for Seagen gets European Union review
• Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy
• Horizon Therapeutics gains afer FTC settles with Amgen over $28B deal (update)
• Horizon Therapeutics jumps after FTC pauses Amgen challenge for settlement talks
• Horizon Therapeutics jumps as FTC withdraws in-house trial on $28B Amgen deal (update)
• Seagen Tukysa combo breast cancer treatment successful in phase 3